Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Application of intravenous immunoglobulin (IVIG) to modulate inflammation in critical COVID-19 – A theoretical perspective

Ahmed Yaqinuddin a, Ayesha Rahman Ambia a, Tasnim Atef Elgazzar a, Maha bint Mishari AlSaud a, Junaid Kashir a,b,*

a Alfaisal University, Riyadh, Saudi Arabia
b Department of Comparative Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

ABSTRACT

COVID-19 is an airway disease that has affected ~125 million people worldwide, caused by a novel coronavirus termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), spread through respiratory droplets, direct contact, and aerosol transmission. Although most patients presenting with absent or mild symptoms recover completely, the highest morbidity and mortality rates are seen in the elderly, and patients with comorbidities such as cardiovascular diseases, cancer, immunosuppressive diseases, diabetes, and pre-existing respiratory illnesses. Several therapeutic strategies have been examined, but a wide-ranging therapeutic option for particularly severe cases of COVID-19 remains to be elucidated. Considering the indications presented by COVID-19 patients who present similarly with inflammatory conditions, intravenous immunoglobulin (IVIG) administration has been examined as a possible route to reduce proinflammatory markers such as ESR, CRP and ferritin by reducing inflammation, based on its anti-inflammatory effects as indicated by utilisation of IVIG for numerous other inflammatory conditions. Herein, summarising the recent key clinical evaluations of IVIG administration, we present our hypothesis that administration of IVIG within a specific dosage would be extremely beneficial towards reducing mortality and perhaps even the length of hospitalisation of patients exhibiting severe COVID-19 symptoms.

Introduction

COVID-19 is an airway disease that has ravaged the medical, social, and economic fabric of the world as we know it, having affected ~125 million people worldwide and resulted in ~2.75 million casualties as of 9:54 am CET, March 27, 2021. The causative underlying factor is a novel coronavirus, termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), spread through respiratory droplets, direct contact, and aerosol transmission [1,80]. As the seventh member of coronaviruses known to infect humans, SARS-CoV2 is an enveloped positive sense ssRNA virus causing respiratory, gastrointestinal, and neurological symptoms in humans, mammals, and birds. Four coronaviruses cause symptoms in immunocompromised patients, while the other two - SARS-CoV, and the middle east respiratory syndrome (MERS)-CoV- had caused epidemics in 2002–2003 in China and 2012 in the Middle East, respectively [2]. Although most patients presenting with absent or mild symptoms recover completely, some patients further deteriorate into life-threatening conditions including acute respiratory distress syndrome (ARDS), multiple organ dysfunction (MODS), and heart failure, all of which suggest a cytokine storm syndrome (CSS) in such patients [3]. The highest morbidity and mortality rates are seen in the elderly, and patients with comorbidities such as cardiovascular diseases, cancer, immunosuppressive diseases, diabetes, and respiratory illnesses [4].

Pathophysiology of COVID-19

COVID-19 attaches to the respiratory epithelium through spike proteins (S), facilitating viral entry into host cells [2,5]. The incubation period ranges from 2 to 14 days, during which SARS-CoV2 transmission can occur [4]. Early symptoms of fever and cough may be followed by viremia which can target organs including the heart, renal, and gastrointestinal tract. Common clinical symptoms include flu-like indications such as fever, cough, fatigue, headache, dysgeusia, pleuritic chest pain, conjunctivitis, sore throat, diarrhea, vomiting and myalgia [6,7].

* Corresponding author at: College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
E-mail address: jkashir@alfaisal.edu (J. Kashir).

https://doi.org/10.1016/j.mehy.2021.110592
Received 22 November 2020; Received in revised form 1 April 2021; Accepted 5 April 2021
Available online 9 April 2021
0306-9877/© 2021 Elsevier Ltd. All rights reserved.
resolution CT (HRCT) is the gold standard for radiological diagnosis in COVID-19, while reverse transcription-PCR (RT-PCR) is used as a diagnostic tool using nasal swabs, bronchoalveolar lavage, or tracheal aspirates, as is serology [8,9].

Patients may recover from any time throughout the course of the disease, or may progress to the next stage, even descending into acute respiratory distress syndrome (ARDS) with or without multiple organ dysfunction syndrome (MODS). In asymptomatic patients, symptoms presented include anosmia, ageusia, asthenia and conjunctivitis, alongside mild lymphopenia. Lung ultrasounds may also show localized B-lines, while HRCT will show localized subpleural ground glass appearance. In patients with mild symptoms, indications such as arthralgia, myalgia, dry cough and fever present with increased lymphopenia, and/or ferritin, LDH and D-Dimer. There is also mild hypoxia (>92, while B-lines are diffuse and lead to pleural line thickening). The CT shows a “ground glass” appearance at this stage [2,7–9].

In moderate stages, patients may present with dyspnea, hypoxia, and arrhythmia. Lab tests show progressive increases in D-dimer and ferritin, with worsening hypoxia and hypercapnia, increased transaminases and triglycerides, and increased IL-6 and CRP. There is also a mild increase in NT-pro BNP and troponin, and reduction in platelets. Lung ultrasounds indicate subpleural consolidation, localized pleural effusion and diffuse B-lines, while CTs indicate a “crazy paving” sign. These symptoms necessitate hospital admission. In severe cases of COVID-19, patients show the worst prognosis. ARDS, SIRS, MODS, shock, heart failure, high fever and DIC are some of the clinical symptoms that require urgent care, while blood work show increased pro-inflammatory markers, ferritin, cytokines, increased NT-proBNP, troponin, and signs of renal failure. Lung US has pleural line thickening due to diffuse B lines and subpleural and alveolar consolidation with air bronchograms [2,7–10]. It is no surprise that CT scan shows “white lung” in alignment with the clinical symptoms and lung US [11]. The ARDS seen in the last stage suggests occurrence of a cytokine storm syndrome (CSS) in COVID-19 patients. Some patients may develop secondary hemophagocytic lymphohistiocytosis (sHLH), usually triggered through viral infections, and culminating in CSS or a macrophage activation syndrome (MAS), resulting in increased mortality of up to 60%.

Use of corticosteroids and other treatments in COVID-19

Several strategies and therapeutic options have been tried and tested since the start of COVID-19 outbreak. The use of short courses of corticosteroids at low-to-moderate dose, for critically ill patients with COVID-19 pneumonia, signs of an exaggerated immune response or in patients with symptoms of myocardial involvement has been recommended [12,13]. A systematic review of 771 publications has concluded that there are no beneficial effects of the use of inhaled corticosteroids in patients with COVID-19. However, withdrawal of ICS in patients with asthma and COPD is not recommended [14]. Dexamethasone is a synthetic corticosteroid approved by the FDA in 1958 for broad-spectrum immunosuppression. The limitations of dexamethasone mainly lies in the fact that although it is helpful in reducing pro-inflammatory cytokines, which is beneficial for the hyper-inflammatory stage in COVID-19 patients, it also suppresses T- and B-cell functions, leading to a loss of immune clearance of the SARS-CoV2 viral load [15].

Antiviral agents such as lopinavir/ritonavir (LPV/RTV) are beneficial for severe or critical cases, especially if used within 12 days of symptom onset as retrieved from retrospective studies from the SARS epidemic, leading to shorter recovery time [16,17]. Another antiviral added to the treatment regimen recently is remdesivir, which is a broad-spectrum antiviral drug for a wide array of RNA viruses, including SARS/MERS-CoV5 and Ebola [18,19]. The use of antimalarials such as chloroquine and hydroxychloroquine for their antiviral activity and their immunomodulatory effects on IL-6 and TNF-a have shown some benefit for early stages and mild symptoms [20,21]. Convalescent plasma containing high-titer neutralizing SARS-CoV2 specific antibody decreases the viral load significantly [22]. Anticoagulant use is indicated through use of heparin considering frequently reported cases of disseminated intravascular coagulation (DIC) and prevalence of abnormal coagulation results, especially markedly elevated D-dimer and FDP in COVID-19 deaths, suggesting an association of DIC with increased mortality rate [23,24].

Hypothesis: Intravenous immunoglobulins (IVIG) could prove beneficial for severe COVID-19 patients

COVID-19 is currently divided into four stages: asymptomatic; mild to moderate symptoms including a fever or flu-like symptoms with dry cough; shortness of breath requiring admission; and finally, acute respiratory distress syndrome (ARDS) needing positive pressure oxygen therapy with intensive care therapy. The most severe stage of COVID-19 also presents with disseminated intravascular coagulation (DIC), systemic inflammatory response syndrome (SIRS), multi-organ dysfunction syndrome (MODS), shock, hepatoplenomegaly, among other serious morbidities [11]. The clinical picture of ARDS shows an increase in erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), and serum ferritin, which are markers of inflammation. While limited at present, specific studies show significant promise for the use of IVIG in treating cases of COVID-19, particularly in cases of severe symptoms (Table 1) [25–30]. We can infer from these that the ARDS is driven by proinflammatory markers, for which IVIG may provide symptomatic relief and cure through its immunomodulatory and anti-inflammatory properties [31]. Indeed, considering the indications presented by COVID-19 patients, we posit that perhaps the administration of high-dose IVIG for such patients who present similarly with inflammatory conditions can reduce proinflammatory markers such as ESR, CRP and ferritin by reducing inflammation. The rationale behind use of IVIG for late-stage COVID-19 is based on its biochemical properties, which has anti-inflammatory effects and is utilized for other inflammatory conditions and infectious diseases as well [3,32].

Evaluation of the hypothesis

The history of IVIG use dates to the 1880s when German Physician E. von Behring first studied the effects of passive immunity through the transfer of serum from sensitized guinea pigs and rabbits to non-immune animals, thus passing on the antibodies from neutralised tetanus or diphtheria broth to the non-immune animals [33]. The biochemical essence of serotherapy lies in the formation of antigen–antibody complexes, and the specificity and diversity of the binding sites for antigens on these antibodies. The use of immunoglobulins (Ig) was first utilized in intramuscular form, but due to painful injections and other side effects, the use of IVIG mechanism of action

The mechanism of action of IVIG seems to vary amongst differing conditions of autoimmunity but seem to contain a common thread of action (Fig. 1; Table 2) [35–37]. Anti-idiotypic antibodies bind to antibodies and neutralize them, while Fc receptors on macrophages are blocked following IVIG. Fcγ receptors on immune cells are saturated at high doses, resulting in their inhibition. FcRs, a protective receptor crucial for regulating IgG half-life, normally binds to IgGs, and is protected from catalysis after being internalised in the endosome. IVIG saturates these receptors, accelerating endogenous IgG breakdown, thus mitigating autoimmune responses [38,39]. IVIG may also inhibit FcγRI or FcγRIII receptors, and perhaps also upregulate FcγRII receptors [40].

IVIG can also block adhesion molecules on leukocytes, leading to
Table 1: Summary of conditions applied and relevant findings from key clinical studies examining the efficacy of intravenous immunoglobulin (IVIG) administration in treating various symptoms of COVID-19.

| Study                | Number of patients | Severity       | Patient treatment                                                                 | Intravenous Immunoglobulin dosage | Considerations                                                                 | Outcome                                                                                     |
|----------------------|--------------------|----------------|--------------------------------------------------------------------------------|-----------------------------------|--------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|
| Xie et al., [25]     | 58                 | Severe/Critical | Oxygen Therapy, Abidor antiviral treatment, Moxifloxacin, Heparin                  | 20 g/day administered either < 48 h or > 48 h following patient admission    | >48 h group required higher dosage of IVIG                                      | IVIG treatment within 48 h resulted in lower morbidity compared to treatment > 48 h after admission. |
| Mohtadi et al., [26] | 5                  | Severe         | Combinations of: Hydroxychloroquine, Kaletra, Oseltamivir, Vancomycin, Levofloxacin, Tavanx, Azithromycin, Ceftriaxone, Meropenem, Imipenem | 25-30 g/day for 5 days            | All patients had been intubated                                                | Clinical and respiratory conditions improved                                                  |
| Cao et al., [27]     | 3                  | Severe         | Combinations of: Supportive care and empirical Moxifloxacin, Methylprednisolone, Lopinavir/ritonavir | 25 g/day for 5 days                | All patients exhibited decreased oxygen saturation                           | Saturated oxygen levels increased resulting in quicker extubating of patients.                 |
| Shao et al., [28]    | 325                | Severe/Critical | N/A                                                                             | <15 g or > 15 g per day            | IVIG-treated patients had higher Acute Physiology and Chronic Health Evaluation and Sequential Organ Failure Assessment scores, higher plasma levels of IL-6 and lactate, and lower lymphocyte count and oxygenation index | IVIG significantly reduced the 28-day mortality, the inflammatory response, and improved some organ functions, but only in critical patients |
| Aljaberi and         | 1                  | Severe/Critical | Ceftriaxone, Doxycycline,                                                      | 40 g every 2 weeks                | Leukopenia (lymphopenia), normal coagulation profile, electrolytes,            | Extubated on Day 13 and discharged on Day 14                                               |

(continued on next page)
anti-inflammatory effects, while also inhibiting C3a and C5a anaphylatoxins and others, preventing the formation of membrane attack complex (MAC). IVIG administration can also inhibit T cell, dendritic cell, monocytes, and macrophage proliferation and differentiation, while also downregulating Th17 responses and upregulating regulatory T cells (Treg) differentiation [37,41–43]. IVIG also exerts cytotoxicity on neutrophils and eosinophils, a process termed antibody-dependent cell-mediated toxicity, or ADCC [35–37].

In animal models, IVIG reduces IL-2 and interferon-γ production by T-cells [44,45], while IVIG preparations contain antibodies against CD4 cells, soluble HLA I and II molecules, chemokine receptor, CCR-5, and T-cell receptor β chain [45–48]. Furthermore, perhaps therapeutic IVIG dosages may restore the balance between Th1 and Th2 cells [49]. IVIG exhibits inhibitory B-cell mediated effects including inhibition of antibody production [50], inhibition of B-cell differentiation [51], and inhibition of production of interleukin-6 and tumour necrosis factor-α [52]. However, IVIG also conversely induces B-cell apoptosis [53], specific B-cells downregulation [54], and regulation of CD5 [55].

IVIG reduces levels of circulating IL-1β in autoimmune conditions such as Kawasaki syndrome [56,57], while up to a 1000-fold increase in levels of IL-1 receptor antagonist was observed following IVIG therapy [58]. However, IVIG remains functionally active in mice strains

---

**Table 1 (continued)**

| Study | Number of patients | Severity | Patient treatment | Intravenous Immunoglobulin dosage | Considerations | Outcome |
|-------|-------------------|----------|-------------------|-----------------------------------|----------------|---------|
| Wishah, [29] | | | Hydroxychloroquine | 2 L/minute oxygen by nasal cannula | and liver 17 function. Flu/RSV panels were negative | |
| Lanza et al., [30] | 1 | Severe/Critical | Hydroxychloroquine Azithromycin | 450 mL (5 mL/kg) at 36 mL/h × 3 days with premedication with antihistamine and rehydration, followed by a decrease in infusion to 28 mL/h and subsequently extended total administration to 4 days | intubation and mechanical ventilation by day 7 Deteriorating respiration and bloodwork | Improvement in clinical and pulmonary function CT scan showed a massive reduction in parenchymal consolidations, Patient discharged with good general condition and stabilized vital signs. |

---

**Fig. 1.** Schematic representation summarising the mechanisms of action of intravenous immunoglobulin (IVIG) administration.
Table 2
Summary of the effects of intravenous immunoglobulin (IVIG) treatment upon components of both innate and acquired immunity.

| Component            | Effect of IVIG on component |
|----------------------|----------------------------|
| **Innate Immunity**  |                            |
| Natural Killer (NK)  | - Increased activation      |
|                      | - Increased cytokine production and degranulation |
|                      | - Increased anti-tumor effect |
|                      | - Migration from blood to tissue |
| Dendritic cells (DCs)| - Decreased endocytosis     |
|                      | - Decreased pro-inflammatory cytokine production |
|                      | - Decreased anti-inflammatory cytokine production |
|                      | - Decreased differentiation  |
|                      | - Increased NK cell-mediated ADCC |
|                      | - Increased expression of MHC class II and co-stimulatory molecules |
|                      | - Decreased DC-mediated T cell activation |
|                      | - Decreased expression of activating FcγR |
|                      | - Increased expression of CD1d |
| Macrophages          | - Increased production of IL-1Ra |
|                      | - Decreased activation       |
|                      | - Decreased production of pro-inflammatory cytokines |
|                      | - Decreased expression of IFN-γR2 |
|                      | - Decreased expression of activating FcγR |
|                      | - Blockade of activating FcγR |
|                      | - Increased expression of inhibitory FcγRiIB |
| Neutrophils          | - Decreased activation due to IgG monomers inhibiting FcγR |
|                      | - Increased activation by IgG dimers binding FcγR or by ANCA |
|                      | - Decreased adhesion to endothelium |
|                      | - Increased death by Siglec |
| **Acquired Immunity**|                            |
| T cells              | - Increased apoptosis        |
|                      | - Decreased IL-2 production |
|                      | - Decreased differentiation  |
|                      | - Decreased activation and proliferation |
| Treg cells           | - Increased production      |
|                      | - Increased suppressive action |
| B cells              | - Increased apoptosis        |
|                      | - Decreased proliferation    |
|                      | - Regulation of antibody production |
|                      | - Increase in inhibitory FcγRiIB |
|                      | - Neutralization of survival factors |
|                      | - Inhibition of activating FcγR |

deficient in IL-1R, IL-4, IL-10, IFN-γR, IL-12β and TNF-α [59], indicating that perhaps cytokine modulation is unlikely the major mechanism of action. TNF-α mediated cytotoxicity is also inhibited by IVIG [60], which is also thought to modulate endothelial cell function by interacting with intercellular adhesion molecules (ICAM) [38,61]. Other possible IVIG mechanisms can also modulate cell migration due to the presence of antibodies against integrins [62] and the arginine-glycine-aspartagine (RGD) cell adhesion motifs [54]. Infusion of IVIG may also restore levels of sialic acid-rich IgG, inducing an anti-inflammatory action [63-65].

**Structure**

Immunoglobulins (Ig) are glycoproteins produced by activated plasma cells in response to antigens and modulate adaptive immune functions in the human body. IgGs are the most abundant immunoglobulin in the human body, with a plasma concentration of 700–1600 mg/dL [35]. The high half-life of IgG (21–25 days) is due to its binding on Fcγ receptors, which in turn protects IgG from lysosomal degradation. One theory on IVIG effect in auto-immune conditions is that IVIG suppresses these Fcγ receptors leading to marked decrease of auto-IgG antibody half-life. It is the same Fcγ blockade that caused an increase in platelets in immune thrombocytopenic purpura (ITP) through IVIG use [39].

IgG consists of two heavy chains and two light chains, which can be broken down into two regions through the action of proteases: an Fab region, responsible for reversible and noncovalent antigen binding; and an Fc region of IgG which binds to macrophages, monocytes, neutrophils and dendritic cells [66]. The Fab region of IgG works through neutralization of the pathogens, preventing attachment to host cells and opsonization or binding of IgG to a pathogen, leading to macrophagic phagocytosis. The Fc region binds to Fcγ receptors on various immune cells leading to either activation or inhibition of immune response. It can induce phagocytosis in macrophages, for example [67]. Other functions include regulation of apoptosis, release of proinflammatory cytokines, upregulation of Fcγ receptors in B cells, maturation and differentiation of immune cells, modulation of antigen-presenting cells, and regulatory T cell function. The IVIG is a highly purified preparation that can also function as the regular Ig in neutralizing exogenous antigens on pathogens as in the case of SARS-CoV2 or endogenous pathogens [10], usually prepared by pooling serum from three thousand to ten thousand donors, which are processed and stabilized for use in autoimmune, inflammatory and degenerative disorders and refractory bacterial and viral infections [49]. The risk of infectious disease transmission is reduced through screening donors, effectively evaluating donor products for infectious products and usage of virus inactivation methods [68,69].

**Clinical use**

IVIG is a standard of care in many primary and secondary immunodeficiency syndromes. Indeed, higher doses of IVIG reduced the occurrence of pneumonia in primary immunodeficiency syndromes. However, this was not the case for chronic airway infections such as chronic sinusitis. IVIG is thought to mount a humoral immune response, which is most commonly deficient in the primary immunodeficiency population. In secondary immunodeficiency syndromes such as AIDS, where patients present with low CD4+ T cell counts, IVIG exhibited protective effects against bacterial, viral and fungal infections [70–72]. Secondary humoral immunodeficiencies are also seen in malnutrition and cancers for which low-dose IVIG is used to reduce life-threatening infections [73].

IVIG can also exert immunomodulating effects on autoimmune disorders such as immune thrombocytopenic purpura (ITP), whereby a high-dose IVIG increased the platelet count and decreased a patient’s need for frequent platelet transfusions [74]. IVIG is also employed in other autoimmune conditions such as idiopathic juvenile arthritis, dermatomyositis, polymyositis, catastrophic antiphospholipid syndrome (CAS), ANCA-related vasculitis and myasthenia gravis. COVID-19 has shown to resemble inflammatory syndromes in its most serious ICU settings, and this is substantiated not only from the clinical picture, but also through serum inflammatory markers such as ESR and CRP [75].

**Dosage**

A low-dose of 400 mg/kg IVIG is given once every three to four weeks for most immunodeficiency syndromes, as a typical part of replacement therapy. However, for inflammatory, auto-immune and infectious etiologies, the dosage used can reach of 2000 mg/kg given across a period of two to five days, often referred to as high dosage. This is because IVIG has a paradoxical effect at high-doses; leading to more immunomodulatory and anti-inflammatory effects [10,35]. A hyperimmune therapy consists of a single intramuscular dose after suspected exposure of a pathogen. Sometimes a hyperimmune therapy is also given as IVIG, such as the respiratory syncytial virus (RSV) IVIG [76].

**Adverse reactions**

Collectively, while the overall safety profile of IVIG is high, certain
risks are also associated with IVIG. For example, IVIG potentially could result in the deposition of antigen–antibody complexes by intradermal injection of antigen into a person who is already sensitized, forming from type-three hypersensitivity reaction, a phenomenon termed the arthus reaction [77]. Most immediate adverse reactions occur within an hour, and range from mild symptoms of headache, fatigue, fever and chills to severe adverse reactions such as myalgia, erythema, flushing, hyper- or hypotension and fluid overload. Transfusion-related acute lung injury (TRALI), acute renal failure, anaphylactic shock, arrhythmias, aseptic meningitis are lesser common immediate adverse reactions. A small percentage of patients have delayed presentation which appear as infections at the transfusion site or renal impairment [78]. Mild to moderate reactions are treated with ceasing the treatment, changing the infusion rate, or applying supportive treatment for the various symptoms. Switching to subcutaneous immunoglobulin (SCIG) is also an option. A non-sugar IVIG preparation may be used to prevent osmotic renal injury in patients with renal failure [79].

Conclusions

Collectively, several strategies and therapeutic options have been examined for efficacy in treatment since the start of COVID-19 outbreak with very mixed results. While promising candidates for treatment have emerged such as Dexamethasone, others have not quite lived up to expectations such as Remdesivir. Even in the case of current success stories, however, modes of treatment that would be able to benefit most COVID-19 patients has yet to be established. To this degree, while a not extensively examined in the context of COVID-19, IVIG presents with a promising avenue of investigation to potentially treat at least those exhibiting severe symptoms. Indeed, the rationale underlying IVIG are its anti-inflammatory effects, being utilized for other inflammatory conditions in the body and should thus remain effective against various variants. However, such aspects are purely hypothetical and would need focussed studies to ascertain efficacy rates.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

The manuscript was conceived by AY and JK, and all authors contributed towards writing the manuscript, which was submitted following approval of all authors. This work was supported by a COVID-19 project grant (#951) awarded by the Saudi Arabian Ministry of Health awarded to AY and JK.

References

[1] Bousey, J., From SARS to 2019-Coronavirus (nCoV): U.S.-China Collaborations on Pandemic Response. 2020, BAND Corporation.
[2] Cdc Weekly C. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) — China. 2020. China Cdc Weekly 2020(20): 113–22.
[3] Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395 (10229):1033–4.
[4] Triggle CR, Bansal D, Farag EABA, Ding H, Sultan AA, Rosenberg HF. COVID-19: learning from lessons to guide treatment and prevention interventions. mSphere 2020;5(3).
[5] Han Q, Lin Q, Ni Z, You L. Uncertainties about the transmission routes of 2019 novel coronavirus. Influenza Other Respir Viruses 2020;14(4):470–1.
[6] Liu K, Fang Y-F, Deng Y, Liu W, Wang M-F, Ma J-P, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J 2020;133(9):1025–31.
[7] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395(10223):507–13.
[8] Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med 2020;288(2):192–206.
[9] Napoli, M.C.M.R.A.C.S.C.D.R.D., Evaluation, and Treatment of Coronavirus (COVID-19) in Treasure Island (FL): StatPears Publishing, 2020.
[10] Prette M, Favino E, Catachicchio G, Racanelli V, Perosa F. SARS-CoV-2 infection complicated by inflammatory syndrome. Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial? Autoimmun Rev 2020;19(7):102559.
[11] Galluccio F, Ergonenc T, Garcia M., A, Allam A-S, Perez-Herrero M, Aguilar R, et al. Treatment algorithm for COVID-19: a multidisciplinary point of view. Clin Rheumatol 2020;39(7):2077–84.
[12] Inzardi RM, Lupi L, Zaccone G, Irala L, Raffo M, Tomasoni D, et al. Cardiac Involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020;5(7):819.
[13] Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet 2020;395(10225):683–4.
[14] Halpin DMG, Singh D, Hadfield RM. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. Eur Respir J 2020;55(5):200009.
[15] Theoharides TC, Conti P. Dexamethasone for COVID-19? Not so fast. J Biol Regul Homeost Agents 2020;34(3).
[16] Chan KS, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J 2020;26(3):399–406.
[17] Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020;382(19):1787–99.
[18] Kupferschmidt K, Cohen J. Race to find COVID-19 treatments accelerates. Science 2020;367(6482):1412–3.
[19] Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30(3):259–71.
[20] Chen Z, et al. Efficacy of high-dose hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. Cold Spring Harbor Laboratory. 2020.
[21] Gaitert P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020;56(1):105949.
[22] Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020;323(16):1582.
[23] Lillicrap D. Disseminated intravascular coagulation in patients with COVID-19. J Thromb Haemost 2020;18(4):786–7.
[24] Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with coronavirus pneumonia. J Thromb Haemost 2020;18(4):844–7.
[25] Xie Y, Cao S, Dong H, Li Q, Chen E, Zhang W, et al. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. J Infect 2020;81(3):318–36.
[26] Mohd-Ali N, Ghayasouri A, Shirazi S, Amazi S, Shafiei E, Bastani E, et al. Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: a case series. Virology 2020;548:1–5.
[27] Cao W, Liu X, Bai T, Fan H, Hong K, Song H, et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis 2020;7(3):oaa102.
[28] Shao, Z., et al., Clinical efficacy of intravenous immunoglobulin therapy in critical patients with COVID-19: A multicenter retrospective cohort study. 2020, medRxiv.
[29] Aljaberi R, Wishah K. Positive outcome in a patient with coronavirus disease 2019 and common variable immunodeficiency after intravenous immunoglobulin. Ann Allergy Asthma Immunol 2020;125(3):349–50.
[30] Lanza M, Polistina GE, Imitazione P, Annunziata A, Di Spirito V, Novella C, et al. Successful intravenous immunoglobulin treatment in severe COVID-19 pneumonia. IDCases 2020;21:e00794.
[31] Nakamura A, Ikeda K, Hamaoka K. Autoimmune-like stimulation of infectious stimuli in Kawasaki disease. Frontiers Pediatrics 2019;7.
[32] Ruan Q, Yang K, Wang W, Jiang L, Song J. Correction to: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020;46(6):1294–7.
[33] Joao C, Negi VS, Kazatchkine MD, Bayry J, Kaveri SV. Passive serum therapy to immunomodulate by IVIG: a fascinating journey of antibodies. J Immunol 2018;200(6):1957–63.
[34] Marrack JR. The chemistry of antigens and antibodies. J Phys Chem 1934;38(7):192–.
[35] Arumugham, V.B. and A. Rayi, Intravenous Immunoglobulin (IVIG), in StatPearls. 2020, StatPears Publishing Copyright © 2020, StatPears Publishing LLC.: Treasure Island (FL).
[36] Bello B. Mechanisms of immune regulation by IVIG. Curr Opin Allergy Clin Immunol 2014;14(6):509–15.
Kondo N, Kasahara K, Kameyama T, Suzuki Y, Shimozawa N, Tomatsu S, et al. Marchalonis JJ, Kaymaz H, Dedeoglu F, Schluter SF, Yocum DE, Edmundson AB. Bouhlal H, Hocini H, Quillent-Gr Stohl W, Elliot JE. In vitro inhibition by intravenous immunoglobulin of human T cell-dependent B cell differentiation induced by staphylococcal superantigens. Clin Lymphocytes. Scand J Immunol 1994;40(1):37–45.

Frank MM, Basta M, Fries LF. The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues. Clin Immunol Immunopathol 1992;52(1):82–6.

Jacob S, Rajabally YA. Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies. Curr Neurropharmacol 2009;7(4):337–42.

Saoudi A, Hurer V, de Kozak Y, Kuhn J, Kaveri SV, Kazatchkine MD, et al. Human immunoglobulin preparations for intravenous use prevent experimental autoimmune uveoretinitis. Int Immunol 1993;5(12):1559–67.

Grose-Wilde H, Blasczyk R, Westhoff U. Soluble HLA class I and class II isotypes and their Cl binding properties. Scand J Immunol 1995;41(5):449–56.

Mollnes TE, Hogasen K, Hoaas BF, Michaelsen TE, Garred P, Harboe M. Inhibition of lymphocyte CD54 and monocyte FcγRII expression in patients with chronic inflammatory neuropathies. J Neuroimmunol 2003;135(1–2):91–5.

Toyoda M, Aukrust P, Froland SS, Liabakk NB, Muller F, Nordoy I, Haug C, et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994;84(7):2136–43.

Crow AR, et al. A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIG? Blood 2006;109(1):155–6.

Stangel M, Schumacher HC, Ruprecht K, Boegner F, Marx P. Immunoglobulins for intravenous use inhibit TNFα cytotoxicity in vitro. Immunol Invest 1997;26(5–7):569–78.

Creange A, Gregson NA, Hughes RAC. Intravenous immunoglobulin modulates lymphocyte CD54 and monocyte FcγRII expression in patients with chronic inflammatory neuropathies. J Neuroimmunol 2003;135(1–2):91–5.

Lapointe BM. IVG therapy in brain inflammation: etiology-dependent differential effects on leucocyte recruitment. Brain 2004;127(12):2649–56.

Kaneko Y. Anti-inflammatory activity of immunoglobulin G resulting from Fc αRI-dependent signal transduction through Fc gamma receptors in B cells. J Exp Med 2005;202(7):1043–50.

Nimmerjahn F, Anthony RM, Ravetch JV. Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc Natl Acad Sci 2007;104(20):8433–7.

Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008;26(1):513–33.

Ferrara, A., G., A., Zulma, M., M., Maeurer, In. Intravenous immunoglobulin (IVIG) for refractory and difficult-to-treat infections. Am J Med 2012. 125(10): p. 1036.e1-1036.e8.

Bournazos S, Ravetch Jv. Diversification of IgG effector functions. Int Immunol 2017;29(7):303–10.

Vyas GN. Inactivation and removal of blood-borne viruses. Transfusion 1995;35(3):307–70.

Trejo SR, Hotta JA, Lebing W, Stenland C, Storms RE, Lee DC, et al. Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process. Vox Sang 2003;85(3):176–87.

Mofenson LM. Prophylactic intravenous immunoglobulin in HIV-infected children with CD4+ counts of 0.20 x 10(9)/L or more. Effect on viral, opportunistic, and bacterial infections. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. JAMA: J Am Med Assoc 1995;273(4):881–8.

Spector SA, Gelber RD, McGrath N, Wara D, Barzilai A, Abrams E, et al. A Controlled trial of intravenous immunoglobulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. N Engl J Med 1994;331(18):1181–7.

Bruton OC. Amanagglutulinemia. Pediatrics 1952;9(6):722–8.

Chinen J, Shearer WT. Secondary immunodeficiencies, including HIV infection. J Allergy Clin Immunol 2010;125(2):319–23.

Solomon CG, Cooper S, Ghanima W. Immune thrombocytopenia. N Engl J Med 2019;381(10):945–55.

Lee K-Y. Pneumonia, acute respiratory distress syndrome, and early immune-modulator therapy. Int J Mol Sci 2017;18(2):388.

Hemming VG. Use of intravenous immunoglobulins for prophylaxis or treatment of infectious diseases. Clin Diagnostic Lab Immunol 2001;8(5):859–63.

Davidoff LM, Seegal BC, Seegal D. The arthus phenomenon. J Exp Med 1932;55(1):93–100.

Sutterlin CF. The new generation of liquid intravenous immunoglobulin formulations (intravenous immunoglobulins, IVIG) for refractory and difficult-to-treat infections. Am J Med 2012. 125(10): p. 1036.e1-1036.e8.

Bournazos S, Ravetch JV. Diversification of IgG effector functions. Int Immunol 2017;29(7):303–10.

Vyas GN. Inactivation and removal of blood-borne viruses. Transfusion 1995;35(3):307–70.

Trejo SR, Hotta JA, Lebing W, Stenland C, Storms RE, Lee DC, et al. Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process. Vox Sang 2003;85(3):176–87.

Mofenson LM. Prophylactic intravenous immunoglobulin in HIV-infected children with CD4+ counts of 0.20 x 10(9)/L or more. Effect on viral, opportunistic, and bacterial infections. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. JAMA: J Am Med Assoc 1995;273(4):881–8.

Spector SA, Gelber RD, McGrath N, Wara D, Barzilai A, Abrams E, et al. A Controlled trial of intravenous immunoglobulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. N Engl J Med 1994;331(18):1181–7.

Bruton OC. Amanagglutulinemia. Pediatrics 1952;9(6):722–8.

Chinen J, Shearer WT. Secondary immunodeficiencies, including HIV infection. J Allergy Clin Immunol 2010;125(2):319–23.

Solomon CG, Cooper S, Ghanima W. Immune thrombocytopenia. N Engl J Med 2019;381(10):945–55.

Lee K-Y. Pneumonia, acute respiratory distress syndrome, and early immune-modulator therapy. Int J Mol Sci 2017;18(2):388.

Hemming VG. Use of intravenous immunoglobulins for prophylaxis or treatment of infectious diseases. Clin Diagnostic Lab Immunol 2001;8(5):859–63.

Davidoff LM, Seegal BC, Seegal D. The arthus phenomenon. J Exp Med 1932;55(1):93–100.

Stein MR. The new generation of liquid intravenous immunoglobulin formulations in patient care: a comparison of intravenous immunoglobulins. Postgrad Med 2010;122(5):176–84.

Gillarda L, Bayry J, Kaveri SV. Intravenous immunoglobulin as clinical immune-modulating therapy. Can Med Assoc J 2015;187(4):257–64.

WHO Coronavirus (COVID-19) Dashboard. (2021). Retrieved 27 March 2021, from https://covid19.who.int/.